JNCCN 360 - MM - News

Advertisement

Advertisement

News

FDA Grants Accelerated Approval to Iberdomide With Daratumumab and Hyaluronidase-fihj and Dexamethasone for Multiple Myeloma

Alpha-Emitting Radioimmunotherapy Shows Activity in Daratumumab-Refractory Myeloma

ASCO 2026: Etentamig Demonstrates Activity After Prior BCMA-Targeted Therapy in Relapsed/Refractory Multiple Myeloma

FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications

ASCO 2026: Mezigdomide Triplet Improves Progression-Free Survival in Relapsed or Refractory Multiple Myeloma

ASCO 2026: Elranatamab Shows Promising Early Activity in High-Risk Smoldering Multiple Myeloma

AACR 2026: Cilta-cel Shows Rapid, Durable Responses in High-Risk Smoldering Myeloma

Copyright © 2026 National Comprehensive Cancer Network, All Rights Reserved